Current status of haploidentical stem cell transplantation for leukemia.
Haploidentical hematopoietic stem cell transplantation has made tremendous progress over the past 20 years and has become a feasible option for leukemia patients without a HLA identical sibling donor. The early complications of severe graft-versus-host disease (GVHD), graft failure and delayed engraftment, as well as disease recurrence have limited the use of this approach. Newer strategies have been applied and overcome some of the problems, including the use of T-cell depleted graft, "mega" dose of stem cells, intensive post-transplant immunosuppression and manipulation of the graft. These have decreased the transplant related mortality and GVHD associated with haploidentical transplantation, however, the major problems of disease relapse and infection, which related to late immune reconstitution, limit the development of haploidentical HSCT. Future challenges remain in improving post-transplant immune reconstitution and finding the best approach to reduce the incidence and severity of GVHD, while preserving graft-versus-leukemia effect to prevent the recurrence of underlying malignancy.
Huang
Xiao-jun
XJ
Institute of Hematology, People's Hospital, Peking University, No 11, Xi Zhi Men South Street, Beijing, 10044, PR China. xjhrm@medmail.com.cn
D006086:Graft vs Host Disease / Q000276:immunology*; D006801:Humans; D007938:Leukemia / Q000601:surgery / Q000628:therapy*; D033581:Stem Cell Transplantation / Q000379:methods* / Q000639:trends*; D014019:Tissue Donors; D014184:Transplantation, Homologous